Palmitoylethanolamide (PEA) Capsules

PEA capsules are recommended by leading pain specialists and practitioners as a safe long term alternative or used in conjunction to traditional prescription pain medication.

Experience natural pain relief and anti-inflammatory support with our premium Palmitoylethanolamide (PEA) capsules with added Quercetin and Luteolin.

PEA offers a safe and effective way to alleviate discomfort and promote overall wellness.

Each capsule is carefully formulated to deliver the optimal dosage of 100% pure Palmitoylethanolamide, a naturally occurring fatty acid amide known for its therapeutic properties.

PEA works by targeting specific receptors in the bod, endocannabinoid system (ECS), helping to reduce pain signals, ease inflammation, and support a healthy immune response.

Take 2 capsules daily (600mg PEA)

Per Serving (2 capsules)

• Palmitoylethanolamide 600mg
• Quercetin 150mg 
• Luteolin 30mg 

NON GMO Free from lactose, gluten, dairy protein, egg, wheat, nuts, yeast and soy protein. Free from artificial colours and flavours.

Fibromyalgia (FM): 35 patients with FM, already taking pain medications, took 600 mg/d of PEA for 12 weeks. Results showed PEA reduced their overall pain. The average number of painful body points also decreased from eight to one.

Osteoarthritis (OA): 111 people with mild or moderate knee OA received 600 mg/d of PEA for 8 weeks, and at the end of the trial, their knee pain and stiffness reduced by 53.7%, compared to 25% in the placebo group.

Diabetic neuropathy: A 600 mg/d dose of PEA across 8 weeks reduced the intensity and presence of pain, pins and needles, burning and numbness in 30 people with diabetic neuropathy.

Carpal tunnel syndrome (CTS): 50 patients took 1,200 mg/d of PEA for 8 weeks, experiencing a decrease in the pain intensity of their CTS, compared to people who didn’t take PEA, whose pain actually increased.

Sciatica: 636 sciatica participants who were prescribed 600 mg/d of PEA for 21 days reported their pain reduced and quality of life improved.

Headache: A total of 636 participants experiencing headache, who were prescribed a daily dosage of 600 mg of palmitoylethanolamide (PEA) for 21 days, reported a reduction in pain and an improvement in their quality of life.

1 Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080/00207454.2018.1503178.

2 Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390/nu11092175.

3 Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111/j.1526-4637.2012.01432.x.

4 Steels E, Venkatesh R, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007/s10787-019-00582-9.

5 Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155/2014/849623.

6 Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.

7 Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.